These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25315189)

  • 1. The high-mobility group nucleosome-binding domain 5 is highly expressed in breast cancer and promotes the proliferation and invasion of breast cancer cells.
    Weng M; Song F; Chen J; Wu J; Qin J; Jin T; Xu J
    Tumour Biol; 2015 Feb; 36(2):959-66. PubMed ID: 25315189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma.
    Zhou X; Yuan B; Yuan W; Wang C; Gao R; Wang J
    Tumour Biol; 2014 Jul; 35(7):6539-47. PubMed ID: 24687550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo.
    Gan Y; Tan J; Yang J; Zhou Y; Dai Y; He L; Yao K; Tang Y
    Med Oncol; 2015 Apr; 32(4):136. PubMed ID: 25796505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMGN5 knockdown sensitizes prostate cancer cells to ionizing radiation.
    Su B; Shi B; Tang Y; Guo Z; Yu X; He X; Li X; Gao X; Zhou L
    Prostate; 2015 Jan; 75(1):33-44. PubMed ID: 25307178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of the nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal cell carcinoma cells in vitro and in vivo.
    Ji SQ; Yao L; Zhang XY; Li XS; Zhou LQ
    J Exp Clin Cancer Res; 2012 Mar; 31(1):22. PubMed ID: 22420896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-340 Suppresses Tumorigenic Potential of Prostate Cancer Cells by Targeting High-Mobility Group Nucleosome-Binding Domain 5.
    Wei P; Qiao B; Li Q; Han X; Zhang H; Huo Q; Sun J
    DNA Cell Biol; 2016 Jan; 35(1):33-43. PubMed ID: 26394192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy.
    Yang C; Gao R; Wang J; Yuan W; Wang C; Zhou X
    Tumour Biol; 2014 Jul; 35(7):6357-63. PubMed ID: 24664583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine.
    Guo Z; Zhang X; Li X; Xie F; Su B; Zhang M; Zhou L
    Oncol Rep; 2015 Mar; 33(3):1519-25. PubMed ID: 25572120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of HMGN5 expression by RNA interference induces cell cycle arrest in human lung cancer cells.
    Chen P; Wang XL; Ma ZS; Xu Z; Jia B; Ren J; Hu YX; Zhang QH; Ma TG; Yan BD; Yan QZ; Li YL; Li Z; Yu JY; Gao R; Fan N; Li B; Yang JL
    Asian Pac J Cancer Prev; 2012; 13(7):3223-8. PubMed ID: 22994738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA-183-3p Inhibits Progression of Human Prostate Cancer by Downregulating High-Mobility Group Nucleosome Binding Domain 5.
    Li Y; He S; Zhan Y; He A; Gong Y; Ji G; Huang C; Peng D; Guan B; Li X; Zhou L
    DNA Cell Biol; 2019 Aug; 38(8):840-848. PubMed ID: 31314587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMGN5 blockade by siRNA enhances apoptosis, suppresses invasion and increases chemosensitivity to temozolomide in meningiomas.
    He J; Liu C; Wang B; Li N; Zuo G; Gao D
    Int J Oncol; 2015 Oct; 47(4):1503-11. PubMed ID: 26315299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing HMGN5 suppresses cell growth and promotes chemosensitivity in esophageal squamous cell carcinoma.
    Liu X; Ma W; Yan Y; Wu S
    J Biochem Mol Toxicol; 2017 Dec; 31(12):. PubMed ID: 28914995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMGN5 promotes invasion and migration of colorectal cancer through activating FGF/FGFR pathway.
    Zhu GJ; Liu F; Xu YG; Zhao CX; Zhao JG; Sun C
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1330-1338. PubMed ID: 33629303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMGN5: a potential oncogene in gliomas.
    Qu J; Yan R; Chen J; Xu T; Zhou J; Wang M; Chen C; Yan Y; Lu Y
    J Neurooncol; 2011 Sep; 104(3):729-36. PubMed ID: 21373965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small interfering RNA targeting HMGN5 induces apoptosis via modulation of a mitochondrial pathway and Bcl-2 family proteins in prostate cancer cells.
    Zhang XY; Guo ZQ; Ji SQ; Zhang M; Jiang N; Li XS; Zhou LQ
    Asian J Androl; 2012 May; 14(3):487-92. PubMed ID: 22504871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nucleosome binding protein NSBP1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells.
    Wahafu W; He ZS; Zhang XY; Zhang CJ; Yao K; Hao H; Song G; He Q; Li XS; Zhou LQ
    Tumour Biol; 2011 Oct; 32(5):931-9. PubMed ID: 21695596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMGN5 expression in bladder cancer tissue and its role on prognosis.
    Wu J; Wang J
    Eur Rev Med Pharmacol Sci; 2018 Feb; 22(4):970-975. PubMed ID: 29509244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research advances in HMGN5 and cancer.
    Shi Z; Tang R; Wu D; Sun X
    Tumour Biol; 2016 Feb; 37(2):1531-9. PubMed ID: 26700674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of microRNA-495 suppresses the proliferation and invasion and induces the apoptosis of osteosarcoma cells by targeting high-mobility group nucleosome-binding domain 5.
    Jiang W; Zheng J; Yu T; Wang J
    Oncol Rep; 2017 Aug; 38(2):1099-1107. PubMed ID: 28627703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis.
    Mou J; Huang M; Wang F; Xu X; Xie H; Lu H; Li M; Li Y; Kong W; Chen J; Xiao Y; Chen Y; Wang C; Ren J
    Mol Cancer Res; 2022 Dec; 20(12):1724-1738. PubMed ID: 36066963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.